does glp 1 cause kidney issues GLP-1 agonists in the treatment of chronic disease in type 2 diabetes and obesity GLP1 Receptor Agonists vs SGLT2-I

L-cell dysfunction has been reported in the DIO models for the GLP-1 reduction 3,4,5

Europe is a growing market as growing obesity rates are leading to an increase in acceptance of GLP-1 therapies and an increased focus on integrated care solutions that include nutrition support and lifestyle support

Kaufman believes that by reducing systemic inflammation, GLP-1 agonists are targeting one of the root causes of these diseases and helping fight reactivated pathogens such as EBV

doi: 10.1093/humupd/dmz019

My appointment was short, maybe 10 minutes

In Colorado, the Medicaid program covers about one out of every eight adults and three out of every ten children